Key terms
About MIST
Milestone Pharmaceuticals, Inc. engages in the development and commercialization of cardiovascular medicines. Its lead product candidate etripamil, is a novel, potent and short-acting calcium channel blocker that is designed as a rapid-onset nasal spray to be self-administered by patients. It develops etripamil to treat paroxysmal supraventricular tachycardia, atrial fibrillation, rapid ventricular rate, and other cardiovascular indications. The company was founded by Philippe Douville and Philippe Lamarre in 2003 and is headquartered in Montreal, Canada.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest MIST news
Apr 09
12:38pm ET
Milestone’s Etripamil Shows Promise in Self-Managed PSVT Treatment
Apr 08
11:39am ET
Milestone: Etripamil ‘effective’ at restoring sinus rhythm in trial
Mar 28
11:37am ET
Milestone’s Etripamil Aims to Revolutionize PSVT Treatment
Mar 28
7:14am ET
Milestone Pharmaceuticals announces resubmission of NDA for etripamil
Mar 22
12:40pm ET
Analysts Offer Insights on Healthcare Companies: Plus Therapeutics (PSTV) and Milestone Pharmaceuticals (MIST)
Mar 22
12:30pm ET
Analysts’ Top Healthcare Picks: Milestone Pharmaceuticals (MIST), Checkpoint Therapeutics (CKPT)
Mar 21
6:25pm ET
Milestone Pharmaceuticals’ Etripamil Nears Approval: A Strong Buy Recommendation
Mar 21
3:07pm ET
Milestone Pharmaceuticals Advances Etripamil Development
Mar 21
7:16am ET
Milestone Pharmaceuticals reports FY23 EPS ($1.39), consensus ($1.37)
Feb 29
10:57am ET
Biotech Alert: Searches spiking for these stocks today
Feb 29
10:57am ET
Biotech Alert: Searches spiking for these stocks today
Feb 29
7:17am ET
Milestone Pharmaceuticals 16.667M share Spot Secondary priced at $1.50
Feb 28
4:43pm ET
Milestone Pharmaceuticals announces offering of common stock, warrants
Feb 28
11:59am ET
Biotech Alert: Searches spiking for these stocks today
Feb 28
11:59am ET
Biotech Alert: Searches spiking for these stocks today
Feb 26
10:45am ET
Milestone Pharmaceuticals Earns Buy Rating on Strong Regulatory and Financial Outlook
Feb 26
7:17am ET
Milestone Pharmaceuticals announces plan to resubmit NDA for etripamil
Jan 22
1:28pm ET
Bullish Outlook on Milestone Pharmaceuticals Amid Regulatory Hurdles: A Buy Rating with a $25 Price Target
No recent press releases are available for MIST
MIST Financials
Key terms
Ad Feedback
MIST Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
MIST Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range
